Study Description
This study is a prospective, open-label, multi-center, non-comparative, observational
study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world
clinical setting in Korean Graft-versus-Host disease (GvHD) patients The dosage and duration of treatment may be considered and decided by the investigator in
accordance with prescribing information of Jakavi®. All participants who receive at least
one dose of the drug and are in the follow-up assessment or early discontinuation
(withdrawal) will be the safety population. This study will enroll patients who are newly
starting Jakavi® and patients who have been taking Jakavi® prior to study participation.
Considering the current clinical practice, a 24 weeks follow-up period of ruxolitinib
treatment is needed to assess the safety and the durable effectiveness of the treatment.
Mandatory additional safety monitoring will be conducted following the last dose of the
treatment for further AE assessments.
Interventions
ruxolitinib
Eligibility Criteria
Inclusion Criteria:
1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi®
treatment according to locally approved label
2. Patients who are willing to provide written informed consent prior to study
enrollment
Exclusion Criteria:
1. Patients under 12 years old
2. Patients with contraindication according to locally approved label of Jakavi®
3. Patients who receive or are going to receive any investigational medicine during the
observation period.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.